Peptide composition targeting glypican 3 and its use
Novel GPC3-binding peptides offer improved therapeutic and diagnostic options for GPC3-related tumors by enhancing targeting specificity and efficacy beyond existing antibody-based treatments.
JP2026519250APending Publication Date: 2026-06-12PEPTIDREAM INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- PEPTIDREAM INC
- Filing Date
- 2024-06-06
- Publication Date
- 2026-06-12
AI Technical Summary
⚠Technical Problem
Current therapies targeting glypican-3 (GPC3) expression in tumors, such as the monoclonal antibody codlituzumab, have shown limited efficacy in clinical trials, highlighting the need for more effective GPC3-binding agents.
⚗Method used
Development of novel peptides, including cyclic peptides, that specifically bind to GPC3 with high avidity, offering potential therapeutic and diagnostic applications by targeting GPC3-overexpressing tumors.
🎯Benefits of technology
These peptides provide enhanced targeting capabilities, potentially improving therapeutic outcomes and diagnostic accuracy for GPC3-related diseases by binding specifically to GPC3, addressing the limitations of existing therapies.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026519250000001_ABST
Abstract
This technology generally relates to peptides that bind to phosphatidylinositol proteoglycan 3 (GPC3), peptides that bind to GPC3, and compositions containing such peptides.
Need to check novelty before this filing date? Find Prior Art